Three wishes for improving clinical drug development in pulmonary fibrosis
- PMID: 36863732
- DOI: 10.1183/13993003.02355-2022
Three wishes for improving clinical drug development in pulmonary fibrosis
Conflict of interest statement
Conflict of interest: H.R. Collard reports grants from National Institutes of Health, participation on a data safety monitoring board or advisory board for National Institutes of Health and Fibrogen, and a leadership role with the Pulmonary Fibrosis Foundation.
Comment on
-
GLPG1205 for idiopathic pulmonary fibrosis: a phase 2 randomised placebo-controlled trial.Eur Respir J. 2023 Mar 2;61(3):2201794. doi: 10.1183/13993003.01794-2022. Print 2023 Mar. Eur Respir J. 2023. PMID: 36328358 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources